A Phase 2 interventional study of ITI-007 and Placebo in Schizophrenia, sponsored by Intra-Cellular Therapies, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-10-03.
Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing lumateperone in Schizophrenia — 3 open to participants now, 3 under way, 2 of them phase 3. lumateperone · Schizophrenia.
Among the 12 studies testing lumateperone in Schizophrenia, this one is the 4th largest by enrollment, is the only one that started in 2011, is one of 3 in phase 2, and was the 1st registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →3 of the 12 studies testing lumateperone in Schizophrenia are open now, in 3 countries. Recruiting first, the newest first:
Louisiana State University Health Sciences Center Shreveport · Sites in United States
Ages 18–65
University of Massachusetts, Worcester · Sites in United States
Ages 18–65
Intra-Cellular Therapies, Inc. · Sites in United States, Colombia, Serbia
Ages 5–17
By country, each count listing its studies:
lumateperone: first FDA approval 2019 (CAPLYTA). What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lumateperone is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 335 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 66 across the 12 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 4 most frequent:
This study is registered under Intra-Cellular Therapies, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Intra-Cellular Therapies, Inc. is the lead sponsor of 41 studies on the registry; 12 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 11 (46%) have results posted.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 50th largest by enrollment of the 176 interventional ones that give a count, is one of 6 that started in 2011, is one of 11 in phase 2, and was the 154th registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing lumateperone in Schizophrenia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT06174116University of Massachusetts, WorcesterMetabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing lumateperone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate whether ITI-007 is effective in reducing symptoms associated with schizophrenia in patients who are having an acute worsening of their psychosis. Patients will be randomly assigned to receive one of two doses of ITI-007, placebo, or a positive control. The primary goal will be to assess the effects of ITI-007 on psychosis. The safety of ITI-007 will also be assessed.
The study will be conducted as a randomized, double-blind, placebo-controlled, multi-center study in patients diagnosed with schizophrenia and an acute exacerbation of psychosis. The efficacy and safety of two dose levels of ITI-007 administered daily for 28 days will be evaluated as compared to placebo; risperidone has been included as a positive control.
Upon completion of the inpatient 28-day Study Treatment Period, patients will be started on standard antipsychotic medication and will be stabilized over a 5-day period before discharge from the study clinic. Patients will be seen for a final outpatient safety evaluation at the End-of-Study visit approximately 2 weeks after discharge.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Lumateperone 42 mg (ITI-007 60 mg tosylate) administered for 28 days
Drug: ITI-007 · Drug: Placebo
Lumateperone 84 mg (ITI-007 120 mg tosylate) administered for 28 days
Drug: ITI-007
Placebo: Capsules containing inactive placebo administered for 28 days
Drug: Placebo
Risperidone: Capsules containing 4 mg risperidone administered for 28 days
Drug: Risperidone
Capsules containing ITI-007 for 28 days
Capsules containing inactive placebo for 28 days
Capsules containing risperidone for 28 days
Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score
The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.
Time frame: Change from baseline to Day 28
Change From Baseline to Day 8 in Positive and Negative Syndrome Scale (PANSS) Total Score
The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.
Time frame: Change from Baseline to Day 8
Change From Baseline to Day 15 in Positive and Negative Syndrome Scale (PANSS) Total Score
The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.
Time frame: Change from Baseline to Day 15
Change From Baseline to Day 22 in Positive and Negative Syndrome Scale (PANSS) Total Score
The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.
Time frame: Change from Baseline to Day 22
| Milestone | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Lumateperone 84 mg (ITI-007 120 mg Tosylate) | Placebo | Risperidone 4 mg |
|---|---|---|---|---|
| Started | 84 | 83 | 85 | 82 |
| Completed | 60 | 64 | 61 | 63 |
| Not completed | 24 | 19 | 24 | 19 |
| Withdrew: Withdrawal by subject | 10 | 11 | 7 | 8 |
| Withdrew: Physician decision | 2 | 1 | 3 | 0 |
| Withdrew: Specific request of sponsor or investigator | 2 | 0 | 1 | 1 |
| Withdrew: Adverse event | 2 | 0 | 1 | 3 |
| Withdrew: Lack of efficacy | 0 | 1 | 6 | 3 |
| Withdrew: Other | 8 | 6 | 6 | 4 |
The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.
| score on a scale | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Lumateperone 84 mg (ITI-007 120 mg Tosylate) | Placebo | Risperidone 4 mg |
|---|---|---|---|---|
| Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score | -13.2 ± 1.7 | -8.3 ± 1.7 | -7.4 ± 1.7 | -13.4 ± 1.7 |
The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.
| units on a scale | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Lumateperone 84 mg (ITI-007 120 mg Tosylate) | Placebo | Risperidone 4 mg |
|---|---|---|---|---|
| Change From Baseline to Day 8 in Positive and Negative Syndrome Scale (PANSS) Total Score | -4.0 ± 1.2 | -4.7 ± 1.2 | -2.6 ± 1.2 | -6.3 ± 1.2 |
The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.
| units on a scale | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Lumateperone 84 mg (ITI-007 120 mg Tosylate) | Placebo | Risperidone 4 mg |
|---|---|---|---|---|
| Change From Baseline to Day 15 in Positive and Negative Syndrome Scale (PANSS) Total Score | -7.8 ± 1.4 | -4.2 ± 1.3 | -4.5 ± 1.3 | -9.6 ± 1.4 |
The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.
| units on a scale | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Lumateperone 84 mg (ITI-007 120 mg Tosylate) | Placebo | Risperidone 4 mg |
|---|---|---|---|---|
| Change From Baseline to Day 22 in Positive and Negative Syndrome Scale (PANSS) Total Score | -10.5 ± 1.6 | -6.6 ± 1.5 | -4.6 ± 1.5 | -10.8 ± 1.6 |
Collected over From signing ICF until end of study procedures (~ weeks) including 28 days of double-blind treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 0/84 (0%) | 0/84 (0%) | 39/84 (46.4%) |
| Lumateperone 84 mg (ITI-007 120 mg Tosylate) | 0/83 (0%) | 0/83 (0%) | 52/83 (62.7%) |
| Placebo | 0/85 (0%) | 1/85 (1.2%) | 28/85 (32.9%) |
| Risperidone 4 mg | 0/82 (0%) | 1/82 (1.2%) | 37/82 (45.1%) |
| Event | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Lumateperone 84 mg (ITI-007 120 mg Tosylate) | Placebo | Risperidone 4 mg |
|---|---|---|---|---|
| Psychotic disordersPsychiatric disorders | 0/84 | 0/83 | 0/85 | 1/82 |
| SchizophreniaPsychiatric disorders | 0/84 | 0/83 | 1/85 | 0/82 |
| Event | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Lumateperone 84 mg (ITI-007 120 mg Tosylate) | Placebo | Risperidone 4 mg |
|---|---|---|---|---|
| SedationNervous system disorders | 6/84 | 17/83 | 6/85 | 5/82 |
| HeadacheNervous system disorders | 17/84 | 15/83 | 11/85 | 7/82 |
| SomnolenceNervous system disorders | 8/84 | 11/83 | 5/85 | 12/82 |
| Blood Creatine Phosphokinase IncreasedInvestigations | 7/84 | 3/83 | 1/85 | 8/82 |
| DizzinessNervous system disorders | 5/84 | 8/83 | 1/85 | 1/82 |
| NauseaGastrointestinal disorders | 6/84 | 8/83 | 1/85 | 4/82 |
| Dry MouthGastrointestinal disorders | 4/84 | 8/83 | 2/85 | 5/82 |
| AkathisiaNervous system disorders | 1/84 | 2/83 | 2/85 | 6/82 |
| Weight IncreasedInvestigations | 5/84 | 5/83 | 6/85 | 5/82 |
| DyspepsiaGastrointestinal disorders | 5/84 | 1/83 | 1/85 | 3/82 |
All Baseline data are presented for patients who received at least one dose of study drug, with the exception of the PANSS total score which is presented for patients who received at least 4 doses of study drug and who had a baseline measurement as well as at least 1 valid post-baseline efficacy measurement.
| Age, Continuous(years) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Lumateperone 84 mg (ITI-007 120 mg Tosylate) | Placebo | Risperidone 4 mg | Total |
|---|---|---|---|---|---|
| Mean | 38.3 ± 10.03 | 41.4 ± 8.92 | 40.5 ± 9.83 | 40.7 ± 9.33 | 40.1 ± 9.56 |
| Sex: Female, Male(Participants) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Lumateperone 84 mg (ITI-007 120 mg Tosylate) | Placebo | Risperidone 4 mg | Total |
|---|---|---|---|---|---|
| Female | 18 | 11 | 20 | 9 | 58 |
| Male | 66 | 72 | 65 | 73 | 276 |
| Race/Ethnicity, Customized(Participants) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Lumateperone 84 mg (ITI-007 120 mg Tosylate) | Placebo | Risperidone 4 mg | Total |
|---|---|---|---|---|---|
| Caucasian/White | 13 | 16 | 17 | 16 | 62 |
| Black or African American | 70 | 62 | 65 | 64 | 261 |
| Asian | 0 | 0 | 1 | 2 | 3 |
| Other | 1 | 5 | 3 | 0 | 9 |
| Positive and Negative Syndrome Scale (PANSS) Total Score(units on a scale) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Lumateperone 84 mg (ITI-007 120 mg Tosylate) | Placebo | Risperidone 4 mg | Total |
|---|---|---|---|---|---|
| Mean | 88.1 ± 11.04 | 84.6 ± 11.63 | 86.3 ± 13.10 | 86.1 ± 12.24 | 86.2 ± 12.04 |
The record gives a start of Dec 2011, a primary completion of Aug 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2025, 12 years 2 months after primary completion. A results delay was requested in Sep 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lumateperone
Intra-Cellular Therapies, Inc. →